iTOL-201
Liver Diseases
PreclinicalActive
Key Facts
About iTolerance
iTolerance is a private, preclinical-stage biotech founded in 2020 and based in Miami, Florida. The company's mission is to eliminate the need for chronic immunosuppression in regenerative medicine through its proprietary iTOL-100 immunomodulatory platform, which utilizes a synthetic FasL protein. Its lead programs, iTOL-101 and iTOL-102, aim to cure Type 1 Diabetes using allogeneic cadaveric islets and stem cell-derived islets, respectively, and have shown promising preclinical results in non-human primates. The company is also exploring other applications, including a liver program (iTOL-201) and a potential program for ovarian insufficiency (iTOL-401).
View full company profileTherapeutic Areas
Other Liver Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| hpSC-Derived Liver Cells | International Stem Cell | Research/Preclinical |